Cost-effectiveness of psoriasis therapy with etanercept in Germany;Kosteneffektivität der psoriasisbehandlung mit etanercept in Deutschland

JDDG - Journal of the German Society of Dermatology

Volumn 5, Issue 9, 2007, Pages 762-768

  Heinen Kammerer, Tatjana ^a   Daniel, Dietmar ^a   Stratmann, Lioba ^a   Rychlik, Reinhard ^a   Boehncke, Wolf Henning ^b  

^a Institute of Empirical Health Economics   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Cost utility; Costs of disease; Etanercept; ICER; Psoriasis; QALY

Indexed keywords

ETANERCEPT;

ARTICLE; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DRUG EFFICACY; GERMANY; HUMAN; PSORIASIS; QUALITY OF LIFE; UNITED KINGDOM;

EID: 34548540542     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06489.x     Document Type: Article

References (39)

1. Schön MP, Boehncke W-H. Plaque-Psoriasis. New Engl J Med 2005, 352 : 1899 1912.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Plaque-Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999, 41 : 401 407.
3. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, Stahle-Backdahl M. Increased risk for cardiovascular mortality in Plaque-Psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004, 19 : 225 230.
4. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke W-H. Plaque-Psoriasis is an independent risk factor for coronary heart disease. Br J Dermatol 2007, 156 : 271 276.
5. Henseler T, Christophers E. Plaque-Psoriasis of early and late onset: charac-terization of two types of Plaque-Psoriasis vulgaris. J Am Acad Dermatol 1985 Sep 13 (3 450 456.
6. Boehncke W-H, Friedrich M, Mrowietz U, Reich K, Rosenbach T, Sticherling M, Thaci D. Stellenwert von Biologics in der Plaque-Psoriasis-Therapie: ein Consensus-Papier der Arbeitsgruppe Plaque-Psoriasis, Arbeits-gemeinschaft Dermatologische Forschung. J Dtsch Dermatol Ges 2003, 1 : 620 628.
7. Finlay AY, Coles AC. The effect of severe Plaque-Psoriasis on the Quality of Life of 369 patients. Br J Dermatol 1995, 132 : 236 244.
8. Finlay AY. Current severe Plaque-Psoriasis and the rule of tens. Br J Dermatol 2005, 152 : 861 867.
9. Boehncke W-H, Brasie RA, Barker J, Chimenti S, Dauden E, de Rie M, Du-bertret L, Giannetti A, Katsambas A, Kragballe K, Naeyaert JM, Ortonne J-P, Peyri J, Prinz JC, Saurat J-H, Strohal R, van de Kerkhof P, Sterry W. Recom-mendations for the use of Etanercept in Plaque-Psoriasis: a European dermatology expert group consensus. JEADV 2006, 20 : 988 998.
10. Nast A, Kopp I, Augustin M, Banditt K-B, Boehncke W-H, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mro-wietz U, Ockenfels H-M, Orzechowski H-D, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, SchmidOtt G, Sebastian M, Streit V, Weberschock T, Rzany B. S3-Leitlinie zur Therapie der Plaque-Psoriasis vulgaris. J Dtsch Dermatol Ges 2006, 4 : Supplement 2.
11. Boehncke W-H, Prinz J, Gottlieb AB. Biologic therapies for Plaque-Psoriasis: a systematic review. J Rheumatol 2006, 33 : 1447 1451.
12. Berger K, Ehlken B, Kuglund B, Augustin M. Cost-of-illness in patients with moderate and severe chronic Plaque-Psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005, 3 : 511 518.
13. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M. Cost of moderate to severe plaque Plaque-Psoriasis in Germany: a multicen-ter cost-of-illness study. Dermatology 2006, 212 : 137 144.
14. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Orme-rod AD. British Association of Dermatologists guidelines for use of biological interventions in Plaque-Psoriasis 2005. Br J Dermatol 2005, 153 : 486 497.
15. CHE/CRD Technology Assessment Group. Efalizumab and Etanercept For The Treatment Of Plaque-Psoriasis. Technology Assessment Report com-missioned by the HTA Programme on behalf of The National Institute for Clinical Excellence (http://www.nice.org.uk/download.aspx?o=260994&template=download.aspx).
16. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspary AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R. A randomized trial of Etanercept as mono-therapy for Plaque-Psoriasis. Archives of Dermatology 2003 139 (12 1627 1632.
17. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB. Etanercept as Monotherapy in Patients with Plaque-Psoriasis. New Eng J Med 2003, 349 (21 2014 2022.
18. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CEM, Nakanishi AM, Zitnik R, van de Kerkhof PCM. A global phase III randomized controlled trial of Etanercept in Plaque-Psoriasis: safety, efficacy, and effect of dose reduction. British Association of Dermatology 2005, 152 : 1304 1312.
19. Pearson SSS, Rawlins M. Quality, Innovation, and Value for Money: NICE and the British National Health Service JAMA 2005 294 : 2618 2611.
20. Leitlinien für gesundheitsökonomische Evaluation in Kanada. http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf.
21. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programms Oxford 1987 : 74.
22. EuroQol Group : EuroQol - a new faci-lity for the measurement of health-related quality of life. Health Policy 16 (1990 199 208.
23. Nelles S, Daniel D, Stratmann L, Irrgang V, Heinen-Kammerer T, Rychlik R, Boehncke WH. Die Plaque-Psoriasis-Krankheitskosten korrelieren mit der Schwere des klinischen Befundes und nicht mit der psychischen Krank-heitslast. Pharmacoeconomics-German Research Articles, im Druck.
24. Einheitlicher Bewertungsmaßstab (EBM). Stand: 1. Oktober 2001. Deutscher Ärzte-Verlag, Köln, 2001.
25. Gebührenordnung für Ärzte (GOÄ). http://www.e-bis.de/ goae/defaultFrame.htm
26. Rote Liste. Editio Cantor Verlag, Aulendorf/Württ, 2004.
27. Gelbe Liste. MediMedia Medizinische Medien Informations GmbH, Neu-Isenburg, 2004.
28. Spitzenverband der Krankenkassen, Verband der privaten Krankenversiche-rung, Deutsche Krankenhausgesellschaft. Nutzungsbedingungen für den Fallpauschalen-Katalog G-DRG-Ver-sion 2007 - Fassung vom 19.09.2006 (http://www.g-drg.de/gdrgSystem2007/nutzung_fpk.php?b=xls).
29. Nast A, Kopp I, Augustin M, Banditt K-B, Boehncke W-H, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels H-M, Orzechowski H-D, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. S3-Leitlinie zur Therapie der Plaque-Psoriasis vulgaris. J Dtsch Dermatol Ges 2006, 4 : Supplement 2.
30. Enbrel 25 mg Fachinformation, Stand: August 2006.
31. Zink A, Kary S, Rau R. Langzeitbeobachtung der Behandlung der rheuma-toiden Arthritis mit Biologika in Deutschland: Behandlungsanamnese und aktuelle Therapie. Poster auf dem 32. Kongress der Deutschen Gesellschaft für Rheumatologie, Frankfurt, 3.-6. September 2003.
32. Gelfand J, Neimann A, Shin D. Risk of myocardial infarction in patients with Plaque-Psoriasis. JAMA 2006 295 : 1735 1741.
33. Schäfer T. Epidemiology of Plaque-Psoriasis - Review and the German Perspective. Dermatology 2006 212 (4 327 337.
34. McGregor M, Caro JJ. QALYs: are they helpful to decision makers? Pharmacoe-conomics 2006 24 (10 947 952.
35. Laschet H. Es gibt keinen, den man richtig packen kann Ärztezeitung 2006 203 : 6.
36. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Methoden. http://www.iqwig.de/index.download. a356e36e87a02176d2305a0c513dc52a.pdf.
37. Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology 2006 45 (8 1029 1038.
38. Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2006 10 (31).
39. Brecht JG, Kruse HP, Mohrke W, Oe-streich A, Huppertz E. Health economic comparison of three recommended drugs for the treatment of osteoporosis. int J Clin Pharmacol Res. 2004 24 (1 1 10.